Mankind Pharma Limited has informed the Exchange about Credit Rating- Revision
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ICRA has reaffirmed Mankind Pharma's credit ratings across its borrowing instruments. The Non-Convertible Debentures of ₹5,000 crore retain their AA+/Stable rating, while the long-term/short-term fund-based limits of ₹1,250 crore keep the AA+(Stable)/A1+ rating. The reaffirmation indicates that the rating agency sees no change in the company's creditworthiness compared to its previous assessment. The company has stated this update will also be available on its official website.
Neutral to mildly positive for shareholders — the reaffirmation of a strong investment-grade AA+ rating signals continued financial stability and easy access to debt markets, but no rating upgrade means no fresh positive surprise for the stock.